Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr 14;18(1):165.
doi: 10.1186/s12967-020-02333-9.

Anti-IL6R role in treatment of COVID-19-related ARDS

Franco Maria Buonaguro  1 , Igor Puzanov  2 , Paolo Antonio Ascierto  3
Affiliations
Editorial

Anti-IL6R role in treatment of COVID-19-related ARDS

Franco Maria Buonaguro et al. J Transl Med. .
No abstract available

Keywords: ARDS; COVID-19; IL-6; SARS-CoV-2; Tocilizumab.

PubMed Disclaimer

Conflict of interest statement

PAA has/had a consultant/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim. He also received research funds from Bristol Myers-Squibb, Roche-Genentech, Array, and travel support from MSD.

IP serves as consultant for Amgen

FMB

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Binqing Fu, Xiaoling Xu, Wei Haiming. Why tocilizumab could be an effective treatment for severe COVID-19? J Trans Med. 2020 doi: 10.1186/s12967-020-02339-3. - DOI - PMC - PubMed
    1. The General Office of National Health Commission Office of State TCM Administration. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6, Revised). http://www.kankyokansen.org/uploads/uploads/files/jsipc/protocol_V6.pdf. Accessed 18 Feb 2020.
    1. Lauder SN, Jones E, Smart K, et al. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur J Immunol. 2013;43(10):2613–2625. doi: 10.1002/eji.201243018. - DOI - PMC - PubMed
    1. Longhi MP, Wright K, Lauder SN, Nowell MA, Jones GW, Godkin AJ, et al. Interleukin-6 is crucial for recall of influenza-specific memory CD4+ T cells. PLoS Pathog. 2008;4(2):e1000006. doi: 10.1371/journal.ppat.1000006. - DOI - PMC - PubMed
    1. Dienz O, Rud J, Eaton S, et al. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol. 2012;5:258–266. doi: 10.1038/mi.2012.2. - DOI - PMC - PubMed

Substances